La Renon Healthcare Pvt. Ltd.

Based in Gujarat, India, and founded by Pankaj Singh (Chairman and MD) in 2007, La Renon Healthcare Pvt. Ltd. operates as a developer and manufacturer of pharmaceutical products. In September 2025, a consortium led by White Oak Capital Management, Siguler Guff, Creador and Avendus PE Investment Advisors acquired approximately 10% minority stake in La Renon Healthcare Pvt.

Ltd for INR 110 billion. The company offers pharmaceutical products and services for various critical illnesses and diseases such as Nephrology, Critical Care, CNS, Gastroenterology, Urology, Cardio-Metabolic, Respiratory, and Gynaecology. Some examples of La Renon's products include Silodosin 8 mg Tablets for Benign Prostatic Hyperplasia, Amisulpride Injection 5mg/2ml for post-operative nausea and vomiting therapy, Alfuzosin 10mg Prolonged Release Tablets for Urology, etc. La Renon also has an in-house research and development (R&D) center, developing formulations and processes, transferring technology to manufacturing facilities like Stanford Labs, a subsidiary.

  La Renon Healthcare Pvt. Ltd. generates revenue by manufacturing and selling branded chronic‑therapy pharmaceutical formulations across nephrology, CNS, gastro, gynaecology and cardio‑diabetology segments, supported by nationwide distribution. The September 2025 enables the company to accelerate growth across chronic therapy segments by strengthening its capital base and attracting global institutional investors.

The partnership with Creador, along with White Oak and Siguler Guff, provides strategic expertise and resources to expand product portfolios, scale operations, and enhance market presence both domestically and internationally.